Axolabs

Axolabs specializes in a new class of drugs whose active ingredients are chemically derived from DNA or RNA, known as oligonucleotides or nucleic acid therapies. Leveraging the company’s years of expertise, it assists clients in achieving success with their oligonucleotide treatments. Axolabs, with branches in Germany and the United States, serves most research teams in the global nucleic acid and oligonucleotide therapy fields, including more than 20 large pharmaceutical enterprises, over 250 biotechnology companies, and more than 30 academic research institutions and venture capital firms.